Eagle Pharmaceuticals, Inc. Revenue
Eagle Pharmaceuticals, Inc. reported Revenue of $64.65 million for the 3-month period ending 2023-06-30, per its 10-Q/A filed 2023-08-09.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2023-08-09
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-06-30 was $64.65M, a 12.80% decline year-over-year.
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-03-31 was $66.31M, a 42.78% decline year-over-year.
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $60.70M, a 43.43% increase year-over-year.
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $65.90M, a 65.36% increase year-over-year.
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $316.61M, a 84.56% increase from fiscal 2021.
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $171.55M, a 8.66% decline from fiscal 2020.
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $187.80M, a 4.13% decline from fiscal 2019.
- Eagle Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $195.89M, a 8.17% decline from fiscal 2018.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-06-30 | $64.65M 10-Q/A · filed 2023-08-09 | $130.95M 10-Q/A · filed 2023-08-09 | $191.65M derived: sum of 3 quarters · filed 2023-08-09 | $257.55M derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | $66.31M 10-Q · filed 2023-05-09 | $127.00M derived: sum of 2 quarters · filed 2023-05-09 | $192.91M derived: sum of 3 quarters · filed 2023-05-09 | $267.04M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-12-31 | $60.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $126.60M derived: sum of 2 quarters · filed 2023-03-23 | $200.74M derived: sum of 3 quarters · filed 2023-08-09 | $316.61M 10-K · filed 2023-03-23 |
| 2022-09-30 | $65.90M 10-Q · filed 2022-11-09 | $140.04M derived: sum of 2 quarters · filed 2023-08-09 | $255.91M 10-Q · filed 2022-11-09 | $298.23M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-06-30 | $74.14M 10-Q/A · filed 2023-08-09 | $190.01M 10-Q/A · filed 2023-08-09 | $232.33M derived: sum of 3 quarters · filed 2023-08-09 | $272.18M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $115.87M 10-Q · filed 2023-05-09 | $158.19M derived: sum of 2 quarters · filed 2023-05-09 | $198.05M derived: sum of 3 quarters · filed 2023-05-09 | $246.17M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $42.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $82.17M derived: sum of 2 quarters · filed 2023-03-23 | $130.30M derived: sum of 3 quarters · filed 2023-03-23 | $171.55M 10-K · filed 2023-03-23 |
| 2021-09-30 | $39.85M 10-Q · filed 2022-11-09 | $87.98M derived: sum of 2 quarters · filed 2022-11-09 | $129.23M 10-Q · filed 2022-11-09 | $179.14M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | $48.12M 10-Q · filed 2022-08-09 | $89.37M 10-Q · filed 2022-08-09 | $139.29M derived: sum of 3 quarters · filed 2023-03-23 | $189.22M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | $41.25M 10-Q · filed 2022-05-09 | $91.17M derived: sum of 2 quarters · filed 2023-03-23 | $141.09M derived: sum of 3 quarters · filed 2023-03-23 | $183.03M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $49.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $99.84M derived: sum of 2 quarters · filed 2023-03-23 | $141.78M derived: sum of 3 quarters · filed 2023-03-23 | $187.80M 10-K · filed 2023-03-23 |
| 2020-09-30 | $49.93M 10-Q · filed 2021-11-09 | $91.87M derived: sum of 2 quarters · filed 2021-11-09 | $137.89M 10-Q · filed 2021-11-09 | $186.14M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $41.94M 10-Q · filed 2021-08-09 | $87.96M 10-Q · filed 2021-08-09 | $136.22M derived: sum of 3 quarters · filed 2021-08-09 | $177.36M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $46.02M 10-Q · filed 2021-05-10 | $94.28M derived: sum of 2 quarters · filed 2021-05-10 | $135.43M derived: sum of 3 quarters · filed 2021-05-10 | $192.13M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $48.26M 10-K · filed 2020-03-02 | $89.41M derived: sum of 2 quarters · filed 2020-11-02 | $146.11M derived: sum of 3 quarters · filed 2020-11-02 | $195.89M 10-K · filed 2022-03-08 |
| 2019-09-30 | $41.15M 10-Q · filed 2020-11-02 | $97.85M derived: sum of 2 quarters · filed 2020-11-02 | $147.63M 10-Q · filed 2020-11-02 | $203.69M derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-06-30 | $56.70M 10-Q · filed 2020-08-10 | $106.49M 10-Q · filed 2020-08-10 | $162.54M derived: sum of 3 quarters · filed 2020-08-10 | $213.88M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $49.78M 10-Q · filed 2020-05-11 | $105.84M derived: sum of 2 quarters · filed 2020-05-11 | $157.18M derived: sum of 3 quarters · filed 2020-05-11 | $216.47M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $56.05M 10-K · filed 2020-03-02 | $107.39M derived: sum of 2 quarters · filed 2020-03-02 | $166.69M derived: sum of 3 quarters · filed 2020-03-02 | $213.31M 10-K · filed 2021-03-05 |
| 2018-09-30 | $51.34M 10-K · filed 2020-03-02 | $110.63M derived: sum of 2 quarters · filed 2020-03-02 | $157.26M 10-Q · filed 2019-11-12 | $204.04M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $59.30M 10-K · filed 2020-03-02 | $105.92M 10-Q · filed 2019-08-08 | $152.71M derived: sum of 3 quarters · filed 2020-03-02 | $215.73M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $46.63M 10-K · filed 2020-03-02 | $93.41M derived: sum of 2 quarters · filed 2020-03-02 | $156.43M derived: sum of 3 quarters · filed 2020-03-02 | $206.54M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $46.78M 10-K · filed 2019-02-28 | $109.81M derived: sum of 2 quarters · filed 2019-02-28 | $159.91M derived: sum of 3 quarters · filed 2019-02-28 | $236.71M 10-K · filed 2020-03-02 |
| 2017-09-30 | $63.02M 10-K · filed 2019-02-28 | $113.13M derived: sum of 2 quarters · filed 2019-02-28 | $189.92M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $50.11M 10-K · filed 2019-02-28 | $126.90M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $76.79M 10-K · filed 2019-02-28 | |||
| 2016-12-31 | $189.48M 10-K · filed 2019-02-28 |